WASHINGTON (Reuters) - A small biotechnology company trying to develop needle-free vaccines won a boost to its efforts on Tuesday with U.S. government approval to test a bird flu skin patch on more people.
Iomai's patch is not a vaccine, but rather delivers what is called an adjuvant -- an immune boosting agent that will be delivered along with a vaccine to try to make it work better.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!